Objective-To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes (death and severe disability) after subarachnoid haemorrhage.
Abstract
Objective-To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes (death and severe disability) after subarachnoid haemorrhage.
Design-Double blind, placebo controlled, randomised trial with three months of follow up and intention to treat analysis. To have an 80% chance with a significance level of 0-05 of detecting a 50% reduction in an incidence of cerebral infarction of 15% a minimum of 540 patients was required.
Setting-Four regional neurosurgical units in the United Kingdom.
Patients-In all 554 patients were recruited between June 1985 and September 1987 out of a population of 1115 patients admitted with subarachnoid haemorrhage proved by the results of lumbar puncture or computed tomography, or both. The main exclusion criterion was admission to the neurosurgical units more than 96 hours after subarachnoid haemorrhage. There were four breaks of code and no exclusions after entry. One patient was withdrawn and in 130 treatment was discontinued early. All patients were followed up for three months and were included in the analysis, except the patient who had been withdrawn.
Interventions-Placebo or nimodipine 60 mg was given orally every four hours for 21 days to 276 and 278 patients, respectively. Treatment was started within 96 hours after subarachnoid haemorrhage.
End points -Incidence of cerebral infarction and ischaemic neurological deficits and outcome three months after entry.
Measurements-Demographic and clinical data, including age, sex, history of hypertension and subarachnoid haemorrhage, severity ofhaemorrhage according to an adaptation of the Glasgow coma scale, number and site of aneurysms on angiography, and initial findings on computed tomography were measured at entry. Deterioration, defined as development of a focal sign or fall of more than one point on the Glasgow coma scale for more than six hours, was investigated by using clinical criteria and by computed tomography, by lumbar puncture, or at necropsy when appropriate. All episodes of deterioration and all patients with a three month outcome other than a good recovery were assessed by a review committee.
Main results-Demographic and clinical data at entry were similar in the two groups. In patients given nimodipine the incidence of cerebral infarction
Introduction
Despite advances that have reduced considerably the risks of operation to secure a ruptured cerebral aneurysm the overall mortality and morbidity during the management of patients with subarachnoid haemorrhage who have survived and not been devastated by the initial ictus has not fallen dramatically. This is mainly because such patients rebleed and have delayed cerebral ischaemia. The management dilemma remains the need to weigh the risk of precipitating cerebral ischaemia by operation against that of rebleeding while awaiting surgery.
Subarachnoid haemorrhage provides the clearest clinical opportunity for pretreating ischaemia, but, although the calcium antagonist nimodipine has been reported to reduce the incidence of delayed cerebral ischaemia after subarachnoid haemorrhage,' 2 definitive evidence is lacking. Previous trials were small and relied on selecting a subgroup of patients with cerebral ischaemia presumed to be due to cerebral vasospasm. Ischaemia may be the result of several factors35 and cannot be attributed simply to an exaggerated contraction of cerebral arteries (vasospasm); thus defining such a subgroup is difficult and ignores any potential benefit of treatment in other causes of ischaemia.
Nimodipine has various effects on the cerebral circulation, not all of which may be beneficial. Cerebrovascular smooth muscle is more sensitive than systemic arterial smooth muscle to changes in extracellular calcium concentration and to calcium antagonists such as nimodipine.6-8 In addition to being a moderate cerebral vasodilator, however, nimodipine impairs cerebrovascular reactivity.9-" Nimodipine does not reduce the incidence or severity of cerebral vasospasm detected by angiography in humans or primates,'2-'7 but it reduces the size of cerebral infarcts in rats when given before but not after occlusion of a cerebral artery. 8 We therefore conducted a prospective trial to establish the effect of nimodipine on the incidence of both ischaemic events and proved cerebral infarction and on outcome after subarachnoid haemorrhage.
Patients and methods
SELECTION OF PATIENTS AND DIAGNOSIS
Eligible patients were admitted to one of four centres (in London, Southampton, Liverpool, and Glasgow) within 96 hours after the onset of symptoms and signs of subarachnoid haemorrhage. This time limit was specified because our hypothesis was that nimodipine should be given soon after the bleed to have a prophylactic effect upon subsequent ischaemia. The diagnosis was confirmed by lumbar puncture or BMJ VOLUME 298
11 MARCH 1989 computed tomography, or both-angiography was not required before admission to the trial. The reasons for exclusion were pregnancy; major renal, hepatic, or pulmonary disease; pre-existing cardiac decompensation or a recent (within six months) myocardial infarction; age below 18 years; a subarachnoid haemorrhage that produced a coma in the The minimum criterion to define deterioration was either development of a focal sign or a decline by more than one point on the Glasgow coma scale for more than six hours. The aetiology of deterioration was investigated by using clinical criteria with results from computed tomography whenever possible; when appropriate it was investigated by lumbar puncture or at necropsy. All episodes of deterioration and all patients whose outcome at three months was not a good recovery were assessed at regular meetings of a review committee comprising representatives from each of the four centres. The review committee assessed outcome blind to allocated treatment. Causes of deterioration were classified as rebleed, cerebral ischaemia or infarction, or other, when the specific complication was recorded. The diagnosis of rebleeding or of ischaemia or infarction was classified as definitive or probable according to whether confirmatory evidence was available from computed tomography, from an operation, or at necropsy.
A patient with two infarcts was counted once for the statistical analysis of cerebral infarction. If a patient had both a rebleed and an infarct he (she) appeared in both analyses. Deterioration in a patient known to have an intracerebral haematoma was deemed to be due to ischaemia if as the new signs developed there was a growing area of low density surrounding a clot that had not itself increased on computed tomography. Outcome was assessed at least three months after entry to the trial according to the five point Glasgow outcome scale2' by a doctor who was not responsible for the patient's early management or by postal or telephone inquiry when a patient had moved out of the region. In patients who were dead or disabled at three months we BMJ VOLUME 298 assessed whether the cause was a direct effect of the initial bleed, cerebral ischaemia or infarction, rebleeding, hydrocephalus, intracranial haematoma, operative complication, another complication of treatment, or other. In five cases there was sudden death with no clinical evidence or evidence from computed tomography, from lumbar puncture, or at necropsy of the cause; these were classified as sudden death of unknown cause.
STATISTICAL ANALYSIS
The two treatment groups were compared for rates of infarction (primary outcome event), poor outcome (secondary outcome event), and rebleeding by using x2 tests. These analyses were supported by a detailed analysis that used stepwise logistic regression to adjust the comparisons for the effects of any chance imbalance in the prognostic factors identified from an earlier study20 with the addition of data from computed tomography. Interaction terms between the prognostic factors and treatment were included in the models to test whether any treatment effects were confined to particular subgroups of patients. The prognostic factors considered in this analysis were age; sex; loss of consciousness at ictus; time from haemorrhage to entry; score on the Glasgow coma scale on entry; limb weakness, neck stiffness, and headache (all on en'try); hypertension (defined by a history of hypertension, receiving hypertensive treatment on entry, or a diastolic blood pressure greater than 100 mmHg on entry); angiographic findings (positive, negative, or not done); and computed tomographic findings (normal, abnormal, or not done).
All clinical data generated during the study were recorded in the patients' record forms by us -the blue National Cash Register copy was sent monthly to Bayer UK (Dr L Porto) to comply with Department of Health and Social Security (clinical trial exemption) regulations, the pink copy to GDM, and the white copies were kept in each centre. GDM and AS (for Bayer UK) analysed the data independently.
Results
Between 
In Liverpool the greatest number of patients were admitted too late for entry (39% (122/310)), the prevalence of loss of consciousness at ictus was lowest (30% (31/103)), lumbar puncture studies were used the most for diagnosis (91% (94/103); range 46-55% in the other centres), and patients had the best overall grade.
In Glasgow the prevalence of aneurysms was greatest (77% (154/199)), including multiple aneurysms (27% (40/ 150 angiograms) ), and the prevalence of reported alcohol abuse was lowest (2% (3/199) ).
Overall, the earlier computed tomography was performed the greater the incidence of significant cisternal blood and hydrocephalus. The incidence of proved aneurysms was lowest in Southampton and London (56 and 60%, respectively).
INFARCTS
Nimodipine reduced significantly the number of primary outcome events -that is, the number of all cerebral infarcts-by 34% (table II) . The number of definite infarcts was reduced by 37% (61 in placebo group, 39 in nimodipine; X2 =6-10, df=1; p=0 014).
There was no evidence that the time from ictus or entry to first infarct was affected by treatment (ictus to infarct: nimodipine 9-0 days, range 1-38; placebo 8 4 days, range 1-40). Late infarcts seemed to be associated with later operations, although the numbers were small. The effect of nimodipine was seen both before and after operation and in patients considered to be too ill for angiography or surgery.
The following factors were individually (rather than independently) associated with the rate of infarction: sex (marginal), loss of consciousness, angiographic findings, centre (marginal), hypertension, findings on computed tomography, and treatment. Adjusting simultaneously for findings on angiography and computed tomography and hypertension removed the effects of sex, loss of consciousness, and centre, but treatment remained highly significant (p<0001). There was no evidence of any interactions between prognostic factors and treatment.
In summary, there was clear evidence of a reduced incidence of infarction in patients given nimodipine. The difference could not be explained by an imbalance in prognostic factors (indeed, adjusting for the prognostic factors if anything pointed to an enhanced benefit), and there was no evidence that the benefit of treatment was confined to a particular subgroup of the patients. OUTCOME Nimodipine reduced significantly the secondary outcome event-namely, the In summary, there was clear evidence that treatment with nimodipine reduced the incidence of a poor outcome. This could not be explained by an imbalance in prognostic factors between the treatment groups. There was no evidence that the benefit of treatment was confined to any particular subgroup of the patients.
REBLEEDS
The incidence of rebleeding, either probable or definite, in patients treated with nimodipine was 9% BMJ VOLUME 298
11 MARCH 1989 compared with 14% in patients given placebo (table  II) . This difference had an observed significance level of 8%. The following factors were individually associated with the risk of rebleeding: age, loss of consciousness, score on Glasgow coma scale (marginal), angiographic findings, hypertension ymarginal), and computed tomographic findings. Adjusting simultaneously for age and angiographic findings removed the effects of the other variables, and there was little evidence of an effect of treatment (p=021). This analysis should be given little weight because there were too few rebleeds to be confident of having identified relevant factors.
BLOOD PRESSURE
Nimodipine reduced progressively over 21 days both systolic (by a mean (SD) of 7 1 (18 5) mmHg; p=005) and diastolic blood pressure (by 3 6 (11-0) mmHg; p=0-094). This effect was possibly slightly more obvious in hypertensive patients, but it was not significant. Treatment had no consistent effect on the natural tendency of the pulse rate to increase progressively for 21 days after a subarachnoid haemorrhage (from a mean of 76 (12) to 85 (15) beats/ minute) or on fluid intake or urine output.
ADVERSE REACTIONS
Twenty seven adverse reactions (17 for nimodipine, 10 for placebo) were reported in 24 patients (14 given nimodipine, 10 given placebo). The highest numbers of reported events were for cardiovascular effects and effects on the liver and bi iary system. Six adverse cardiovascular events were reported in the group given nimodipine (three of headache, one of flushing, one of hypertension, and one of hypotension) and three in the group given placebo (two of hypotension and one of headache).
Four adverse events concerned with the liver and biliary system were reported in patients given nimodipine (two of jaundice, two of liver function abnormalities) and five in those given placebo (one of jaundice, four of liver function abnormalities). Apart from two events of rash with nimodipine and one of rash with placebo all other adverse reactions were reported on only one occasion in both groups. The adverse reaction was considered to be sufficiently severe in eight patients taking nimodipine and three taking placebo for the treatment to be withdrawn. Routine haematological and biochemical laboratory data were comparable between the two groups.
Discussion
Our results show that oral nimodipine 60 mg every four hours is well tolerated and reduces cerebral infarction and improves outcome after subarachnoid haemorrhage. This effect of treatment is seen in all clinical grades of patients both before and after operation. Although it is generally accepted that the peak incidence of delayed ischaemia is around seven to 10 days after the initial bleed, the need for early and also prolonged treatment was shown by the occurrence of infarction as soon as the first day and as late as the 40th day aftter the initial bleed-only 37% of episodes of infarction occurred from the seventh to the 10th day.
Deterioration due to cerebral infarction was chosen as the primary outcome event for several reasons. Firstly, given the known actions of nimodipine, we considered that any beneficial effect would be shown through a prophylactic effect" and a reduced occurrence of such episodes. Secondly, although nimodipine might help to preserve neuronal integrity in ischaemia, many other factors, including specific treatments such as induced hypertension, contribute to the natural recovery of function that occurs in some patients with delayed ischaemic deterioration.4 As a result the proportion of patients who are permanently disabled owing to ischaemia may provide a less sensitive assessment of a prophylactic measure. Furthermore, infarction can be diagnosed by clinical observation by sequential computed tomography, and at necropsy. We intentionally did not interpret particular episodes as being due to cerebral vasospasm. Arterial narrowing detected by angiography is only one of the many factors that lead to cerebral ischaemia after subarachnoid haemorrhage. Others include raised intracranial pressure (haematoma, hydrocephalus); episodes of hypotension, hypoxia, hypovolaemia, or hyponatraemia; predisposing factors (history of hypertension, advancing age, cigarette smoking); and surgery to clip the aneurysm.45 Indeed, cerebral vasospasm alone seldom precipitates critical cerebral ischaemia unless the cerebral circulation can no longer compensate for proximal arterial constriction by dilatation of distal cerebral arterioles. So many factors contribute to delayed cerebral ischaemia that an appropriate subgroup would be difficult to define. Anyway, beneficial effect of nimodipine was seen in all the patients.
The assessment of outcome by the Glasgow outcome scale is widely accepted. To avoid unduly relying on the distinction between good recovery and moderate disability because such a distinction is particularly subject to variability in observers we distinguished poor outcomes (death, persistent vegetative state, and severe disability) from good recovery and moderate disability combined. The effect on outcome was greater perhaps than we would have expected from the reduction in the number of cerebral infarcts detected by computed tomography, given that there are other causes of bad outcome. Studies at necropsy have shown that cerebral infarcts may be small and diffusely distributed' and hence beyond the resolution of computed tomography. Nimodipine might protect partially against such minor diffuse infarction. We found no evidence that the beneficial effect of nimodipine was restricted to men, contrary to a recent study of patients with stroke. 26 Results compatible with our findings were obtained in smaller controlled trials ( Is intravenous nimodipine more effective than oral nimodipine? Although it is difficult to compare the patient populations, the reduction in the incidence of bad outcomes with intravenous nimodipine (23% in the study of Ohman and Heiskanen28 and 36% in that of Jan et al29) is similar to that in our study (40%). During intravenous infusion (2 mg/h) the mean plasma concentration was reported to be (1 8) ng/ml, while during oral treatment (45 mg every four hours) the peak plasma concentration an hour after each dose ranged from 7 to 96 ng/ml and was 13 2 ng/ml (range <3-38-8 ng/ml) immediately before each tablet was taken. 30 The area under the curve was similar for the two methods of administration."' Because protein binds 98% of the drug the ratio of cerebrospinal fluid to plasma concentration is only 0 005-the concentration in cerebrospinal fluid was 0 3 (0 2) ng/ml compared with 77 (34) 35 Would a higher dose have any greater effect? A Canadian study used 90 mg every four hours and, although it was a smaller study of patients with a poor grade, showed no significant hypotensive effects,'7 but the effects on overall outcome were much less clear cut than in our trial. An unpublished study (Bayer trial No 3247/3293) comparing 30, 60 , and 90 mg orally every four hours did not show additional benefit with the 90 mg dose when compared with the 60 mg dose. In theory, a patient who metabolises nimodipine quickly might develop ischaemia and would benefit from a higher dose.
For how long should nimodipine be used? There was no evidence after nimodipine was discontinued of a late incidence of cerebral infarction compared with placebo. Any late infarcts seemed to occur after late operations. Prophylactic treatment should start therefore before any operation, whatever its timing. The effect of treatment was independent of when patients were given nimodipine within the 96 hours after ictus. The experimental data show that pretreatment within 20-30 minutes after occlusion of the middle cerebral artery in rats is protective.' Cerebral ischaemia after subarachnoid haemorrhage is progressive so it is not surprising that nimodipine may be helpful even after clinical deterioration starts,'9 but prophylaxis is to be preferred. Patients with negative results on high quality cerebral angiograms are at low risk of rebleeding or cerebral ischaemia and stopping nimodipine treatment might be considered to reduce costs. Exploratory analysis suggests, however, that there is still a trend in favour of nimodipine.
The mechanism of the beneficial effect ofnimodipine is unclear. The original rationale for using calcium antagonists after subarachnoid haemorrhage was to reduce cerebral arterial spasm as seen on angiography. Our We diagnosed atherosclerosis by radiographic detection of calcified deposits in the abdominal aorta.6 Lateral radiographs of the lumbar spine were available
